- Market cap
- Revenue
- Net income
- Cash on hand
- Gross margin
- Net margin
- EPS
- P/E ratio
Presentations demonstrate beneficial role for CyPath Lung in veteran lung cancer care NAVREF 2026 focuses on innovative research to improve healthcare for veterans SAN ANTONIO, Texas – September 22, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced […]
Dual patent protection in Hong Kong and China strengthens CyPath Lung’s positioning to enter Asian market Asia accounts for nearly two-thirds of lung cancer cases worldwide SAN ANTONIO, Texas – September 17, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung […]
BIAF continues to be listed and traded on Nasdaq SAN ANTONIO, Texas – September 9, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive healthcare solutions for the early detection and monitoring of lung disease, today announced that it has received written notice from The Nasdaq Stock Market LLC stating that […]
SAN ANTONIO, Texas – September 3, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics for the early detection of lung cancer and other lung diseases, today announced that President and CEO Maria Zannes will present a corporate update and hold one-on-one investor meetings during the H.C. Wainwright 28th Annual […]
More than 680,000 Americans living with a history of lung cancer represent a significant population requiring ongoing surveillance Noninvasive CyPath® Lung has the potential to complement imaging in monitoring for lung cancer recurrence and new cancers SAN ANTONIO, Texas – September 1, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company developing noninvasive […]
SAN ANTONIO, Texas – August 20, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on the need for noninvasive tests for the detection of early-stage cancer, today announced that it will effect a 1-for-15 reverse split of its common stock. Commencing with the opening of trading on the Nasdaq Capital Market […]
New partner’s national sales force will market CyPath Lung to federal healthcare agencies, including VA medical centers nationwide Agreement significantly expands bioAffinity’s commercial reach through AvMEDICAL’s existing sales team Service-Disabled Veteran-Owned AvMEDICAL provides access to established government procurement channels SAN ANTONIO, Texas – August 18, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology […]
SAN ANTONIO, Texas – August 14, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has closed its previously announced private placement priced at-the-market under Nasdaq rules for the purchase and sale of pre-funded warrants to purchase an aggregate of 8,462,027 […]
SAN ANTONIO, Texas – August 13, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; BIAFW), a biotechnology company focused on noninvasive diagnostics and early cancer detection, today announced that it has entered into a securities purchase agreement with an institutional investor to sell 8,462,027 shares of common stock (or pre-funded warrants in lieu thereof), together with […]
CyPath Lung test volume increased 216% year over year in Q2 2026 Company drives physician adoption of CyPath Lung and advances longitudinal clinical trial Pipeline expands to include development of precision diagnostics for asthma and COPD and dermally delivered skin cancer therapeutics SAN ANTONIO, Texas – August 7, 2026 – bioAffinity Technologies, Inc. (Nasdaq: BIAF; […]
